Table 4.
The clinicopathological findings of renal biopsy based on different clinical indications.
| Pathological diagnosis | Clinical indications | |||||||
|---|---|---|---|---|---|---|---|---|
| NS, N (%) | Nephritic syndrome, N (%) | ANS, N (%) | RPGN, N (%) | AUA, N (%) | AKI, N (%) | CKD, N (%) | Total, N (%) | |
| MN | 6,848 (38.18) | 1,712 (13.69) | 7 (7.78) | 6 (1.20) | 22 (9.91) | 4 (0.60) | 45 (1.67) | 8,644 (24.96) |
| IgAN | 1,996 (11.13) | 4,965 (39.69) | 35 (38.89) | 35 (7.00) | 112 (50.45) | 60 (8.96) | 1,140 (42.21) | 8,343 (24.09) |
| MCD | 3,615 (20.15) | 80 (0.64) | 0 (0) | 1 (0.20) | 0 (0) | 7 (1.04) | 7 (0.26) | 3,710 (10.71) |
| FSGS | 613 (3.42) | 164 (1.31) | 1 (1.11) | 0 (0) | 2 (0.90) | 7 (1.04) | 63 (2.33) | 850 (2.45) |
| MPGN | 109 (0.61) | 91 (0.73) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 10 (0.37) | 210 (0.61) |
| C3 glomerulopathy | 17 (0.09) | 17 (0.14) | 1 (1.11) | 3 (0.60) | 2 (0.90) | 2 (0.30) | 6 (0.22) | 48 (0.14) |
| Postinfectious GN | 59 (0.33) | 59 (0.47) | 42 (46.67) | 3 (0.60) | 2 (0.90) | 5 (0.75) | 6 (0.22) | 176 (0.51) |
| MN + IgAN | 348 (1.94) | 101 (0.81) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.07) | 451 (1.30) |
| MCD + IgAN | 92 (0.51) | 5 (0.04) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 97 (0.28) |
| LN | 1,120 (6.24) | 1,389 (11.10) | 0 (0) | 18 (3.60) | 0 (0) | 18 (2.69) | 71 (2.63) | 2,616 (7.55) |
| HSPN | 753 (4.20) | 956 (7.64) | 0 (0) | 0 (0) | 29 (13.06) | 0 (0) | 174 (6.44) | 1,912 (5.52) |
| HBV-GN | 794 (4.43) | 146 (1.17) | 1 (1.11) | 0 (0) | 3 (1.35) | 0 (0) | 6 (0.22) | 950 (2.74) |
| DN | 562 (3.13) | 199 (1.59) | 0 (0) | 0 (0) | 15 (6.76) | 6 (0.90) | 157 (5.81) | 939 (2.71) |
| ORG | 16 (0.09) | 424 (3.39) | 0 (0) | 0 (0) | 4 (1.80) | 0 (0) | 19 (0.70) | 463 (1.34) |
| paraprotein-GN | 295 (1.64) | 71 (0.57) | 0 (0) | 0 (0) | 1 (0.45) | 1 (0.15) | 20 (0.74) | 388 (1.12) |
| pauci-immune GN | 12 (0.07) | 27 (0.22) | 2 (2.22) | 251 (50.20) | 0 (0) | 8 (1.19) | 29 (1.07) | 329 (0.95) |
| Anti-GBM | 1 (0.006) | 3 (0.02) | 0 (0) | 13 (2.60) | 0 (0) | 1 (0.15) | 7 (0.26) | 25 (0.07) |
| AIN | 1 (0.006) | 22 (0.18) | 0 (0) | 58 (11.60) | 0 (0) | 222 (33.13) | 92 (3.41) | 395 (1.14) |
| ATN | 0 (0) | 40 (0.32) | 0 (0) | 14 (2.80) | 0 (0) | 227 (33.88) | 62 (2.30) | 343 (0.99) |
| CTIN | 0 (0) | 6 (0.05) | 0 (0) | 0 (0) | 0 (0) | 4 (0.60) | 62 (2.30) | 72 (0.21) |
| Cast nephropathy | 4 (0.02) | 15 (0.12) | 0 (0) | 2 (0.40) | 0 (0) | 10 (1.49) | 43 (1.59) | 74 (0.21) |
| Hypertensive nephrosclerosis | 18 (0.10) | 211 (1.69) | 0 (0) | 4 (0.80) | 0 (0) | 20 (2.99) | 204 (7.55) | 457 (1.32) |
| TMA | 26 (0.14) | 59 (0.47) | 1 (1.11) | 0 (0) | 0 (0) | 16 (2.39) | 35 (1.30) | 137 (0.40) |
| HCRD | 23 (0.13) | 97 (0.78) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 17 (0.63) | 137 (0.40) |
| Miscellaneous | 616 (3.43) | 1,650 (13.19) | 0 (0.00) | 92 (18.40) | 30 (13.51) | 52 (7.76) | 424 (15.70) | 2,864 (8.27) |
| Total (%) | 17,938 (100) | 12,509 (100) | 90 (100) | 500 (100) | 222 (100) | 670 (100) | 2,701 (100) | 34,630 (100) |